MX2021016044A - Composiciones de diclorfenamida y metodos de uso. - Google Patents
Composiciones de diclorfenamida y metodos de uso.Info
- Publication number
- MX2021016044A MX2021016044A MX2021016044A MX2021016044A MX2021016044A MX 2021016044 A MX2021016044 A MX 2021016044A MX 2021016044 A MX2021016044 A MX 2021016044A MX 2021016044 A MX2021016044 A MX 2021016044A MX 2021016044 A MX2021016044 A MX 2021016044A
- Authority
- MX
- Mexico
- Prior art keywords
- dichlorphenamide
- methods
- compositions
- pharmaceutical composition
- granules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se provee una composición farmacéutica que comprende: (a) gránulos que comprenden diclorfenamida, o una sal farmacéuticamente aceptable de la misma, y uno o más excipientes intragranulares; y una porción extragranular que comprende por lo menos un modificador de liberación. También se provee un proceso para la preparación y métodos para el uso de la composición farmacéutica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962863125P | 2019-06-18 | 2019-06-18 | |
PCT/US2020/037169 WO2020257037A1 (en) | 2019-06-18 | 2020-06-11 | Dichlorphenamide compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021016044A true MX2021016044A (es) | 2022-04-06 |
Family
ID=74040675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021016044A MX2021016044A (es) | 2019-06-18 | 2020-06-11 | Composiciones de diclorfenamida y metodos de uso. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210290542A1 (es) |
EP (1) | EP3972579A4 (es) |
JP (1) | JP2022536955A (es) |
KR (1) | KR20220035119A (es) |
CN (1) | CN114945362A (es) |
AU (1) | AU2020296816A1 (es) |
BR (1) | BR112021025455A2 (es) |
CA (1) | CA3143958A1 (es) |
CO (1) | CO2021018010A2 (es) |
IL (1) | IL289073A (es) |
MX (1) | MX2021016044A (es) |
WO (1) | WO2020257037A1 (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2835702A (en) * | 1956-05-02 | 1958-05-20 | Merck & Co Inc | Benzene 1, 3 disulfonamides possessing diuretic properties |
US3323997A (en) * | 1964-07-16 | 1967-06-06 | Merck & Co Inc | Synergistic diuretic composition |
CN100551363C (zh) * | 2003-10-10 | 2009-10-21 | 生命周期药物公司 | 包含贝特的固体剂型 |
WO2005051325A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol compositions methods of treatment and delivery |
WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
NZ572207A (en) * | 2006-03-24 | 2012-02-24 | Auxilium Int Holdings Inc | Stabilized compositions containing alkaline labile drugs |
US8105625B2 (en) * | 2007-04-05 | 2012-01-31 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
US8071557B2 (en) * | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
WO2013067170A1 (en) * | 2011-11-03 | 2013-05-10 | Gtx, Inc. | Pharmaceutical compositions of selective androgen receptor modulators and methods of use thereof |
WO2016130650A1 (en) * | 2015-02-11 | 2016-08-18 | Theravance Biopharma R&D Ip, Llc | (2s, 4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor |
US20200163911A1 (en) * | 2018-11-27 | 2020-05-28 | Strongbridge Dublin Limited | Methods of treating disease with dichlorphenamide |
-
2020
- 2020-06-11 AU AU2020296816A patent/AU2020296816A1/en not_active Abandoned
- 2020-06-11 JP JP2021575311A patent/JP2022536955A/ja active Pending
- 2020-06-11 KR KR1020227001229A patent/KR20220035119A/ko unknown
- 2020-06-11 WO PCT/US2020/037169 patent/WO2020257037A1/en unknown
- 2020-06-11 CN CN202080057447.6A patent/CN114945362A/zh active Pending
- 2020-06-11 MX MX2021016044A patent/MX2021016044A/es unknown
- 2020-06-11 EP EP20825983.8A patent/EP3972579A4/en not_active Withdrawn
- 2020-06-11 BR BR112021025455A patent/BR112021025455A2/pt not_active Application Discontinuation
- 2020-06-11 CA CA3143958A patent/CA3143958A1/en active Pending
-
2021
- 2021-01-18 US US17/151,405 patent/US20210290542A1/en active Pending
- 2021-12-16 IL IL289073A patent/IL289073A/en unknown
- 2021-12-28 CO CONC2021/0018010A patent/CO2021018010A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20210290542A1 (en) | 2021-09-23 |
AU2020296816A1 (en) | 2022-02-10 |
EP3972579A4 (en) | 2023-07-05 |
CA3143958A1 (en) | 2020-12-24 |
JP2022536955A (ja) | 2022-08-22 |
WO2020257037A1 (en) | 2020-12-24 |
CO2021018010A2 (es) | 2022-04-19 |
EP3972579A1 (en) | 2022-03-30 |
IL289073A (en) | 2022-02-01 |
CN114945362A (zh) | 2022-08-26 |
BR112021025455A2 (pt) | 2022-03-03 |
KR20220035119A (ko) | 2022-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009475A (es) | Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
AU2018231044A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
RS54329B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS | |
MX2019003099A (es) | Composicion farmaceutica. | |
WO2018183089A8 (en) | Compositions for treating and/or preventing cancer | |
MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
WO2019194773A3 (en) | The combination comprising linagliptin and metformin | |
MX2020011453A (es) | Combinaciones para tratar el cancer. | |
WO2019203771A3 (en) | Solid oral pharmaceutical compositions comprising sitagliptin | |
MX2013001637A (es) | Composiciones farmaceuticas de liberacion controlada oral de blonanserina. | |
EP3648745A4 (en) | PHARMACEUTICAL COMPOSITION CONSISTING OF A MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND A PHARMACEUTICAL SALT OF THE SAME, AND PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITION | |
MX2022004209A (es) | Formas cristalinas de estado solido de un modulador selectivo de canales de potasio. | |
MX2021010596A (es) | Composicion farmaceutica que contiene oseltamivir. | |
MX2021016044A (es) | Composiciones de diclorfenamida y metodos de uso. | |
WO2019151964A3 (en) | Orally disintegrating formulations of saxagliptin | |
ZA202200331B (en) | Naltrexone formulation | |
WO2018069805A3 (en) | Method for preparation of liquid oral composition of l-thyroxin | |
MX2022002356A (es) | Forma de dosificacion oral solida que comprende naproxeno y vitamina b12. | |
PH12021550323A1 (en) | Dendrimer formulations | |
MX2020007494A (es) | Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas. | |
MX2019005005A (es) | Tableta de liberacion extendida que comprende un farmaco de perdida de peso. | |
WO2020013776A3 (en) | Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation | |
MX2019008847A (es) | Profarmacos de cisteamina. | |
WO2018004497A3 (en) | Surfactants for treatment of conditions through targeted necrosis |